<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080494</url>
  </required_header>
  <id_info>
    <org_study_id>11-036</org_study_id>
    <nct_id>NCT02080494</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid in Orthopaedic Trauma Surgery</brief_title>
  <official_title>Tranexamic Acid in Orthopaedic Trauma Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tennessee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Tennessee</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tranexamic acid is an antifibrinolytic drug that has been used to decrease post-operative
      blood loss. This study is a prospective, randomized controlled trial investigating the use of
      tranexamic acid in fracture surgery around the hip and knee, in which significant blood loss
      (&gt;300mL) is expected.

      The hypothesis of this study is that tranexamic acid will be associated with a decrease in
      post-operative blood loss, as well as a decreased need for allogenic blood transfusion, in
      patients who have fracture surgery around the hip and knee.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemoglobin value</measure>
    <time_frame>through postoperative day four</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>hematocrit value</measure>
    <time_frame>through postoperative day four</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of units of allogenic blood transfused</measure>
    <time_frame>through postoperative day four</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Blood Loss</condition>
  <condition>Trauma</condition>
  <condition>Fracture</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No tranexamic acid given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic Acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>15 mg/kg preoperative IV dose followed by another 15 mg/kg IV dose three hours after the initial dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <arm_group_label>Tranexamic Acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with isolated fractures of the pelvic ring, acetabulum, femur or tibia that
             will require open reduction and internal fixation

          -  Expected blood loss is greater than 300 mL

          -  Age â‰¥ 18

          -  Skeletal maturity

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Patients taking oral contraceptives

          -  Contraindication to venous thromboembolic event (VTE) prophylaxis (intracranial,
             intrathoracic, intra-abdominal bleeding or spine fractures)

          -  Patients requiring operative intervention for other injuries (orthopaedic or
             non-orthopaedic)

          -  Known hypercoagulable state including history of prescribed anti-coagulation
             (warfarin, plavix, low molecular weight heparin)

          -  Renal Insufficiency (creatinine greater than 1.5mg/dL)

          -  Open fractures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk W Kiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UTCOM Chattanooga / Erlanger Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Erlanger Health System</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <last_update_submitted>July 6, 2015</last_update_submitted>
  <last_update_submitted_qc>July 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tranexamic acid</keyword>
  <keyword>orthopaedic trauma</keyword>
  <keyword>pelvic fracture</keyword>
  <keyword>hip fracture</keyword>
  <keyword>femur fracture</keyword>
  <keyword>blood loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

